Health Condition 1: A920- Chikungunya virus disease
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Able and willing to complete informed consent process with understanding of the purpose and procedures of the study Medical history and physical examination without clinically significant findings at the time of screening
Exclusion criteria
Exclusion criteria: Pregnant and lactating women History of active viral infection History of immune deficiency or autoimmune disease Have active or history of arthritis within the last 6 months from date of screening Have an active or history of malignant conditions including haematological malignancy Have a history of degenerative neurological disease Have received any vaccination within 4 weeks prior to this study Participants from the vaccine study who have received the Chikungunya vaccine Have received blood transfusion or immunoglobulin within 30 days prior to vaccination in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Based on the Plasma Proteome Database the end point of the present study is to identify at least 500 proteins among which 50 proteins are expected to be differentially expressed These differentially expressed proteins may help to discover newer vaccine for chikungunya infection in near future Proteomic analysis of plasma protein will also identify surrogate marker for diagnosis and prognosisTimepoint: September 2019 | — |
Secondary
| Measure | Time frame |
|---|---|
| Based on the Plasma Proteome Database the end point of the present study is to identify at least 500 proteins among which 50 proteins are expected to be differentially expressed These differentially expressed proteins may help to discover newer vaccine for chikungunya infection in near future Proteomic analysis of plasma protein will also identify surrogate marker for diagnosis and prognosisTimepoint: 12 months | — |
Countries
India
Contacts
Professor Seth GS Medical College and KEM Hospital Parel Mumbai 400012